Future Cardia aims to transform how heart disease is monitored.
It’s a medical-technology (medtech) startup developing an implantable cardiac-monitoring device. This company has raised more than eight million dollars and graduated from two top startup accelerators: Stanford StartX and Johnson & Johnson Innovation Labs’ “JLABS.”
Over the past thirteen years, several startups that went through Stanford StartX have reached unicorn status — i.e., a private company worth at least one billion dollars.
Future Cardia’s device is a tiny, under-the-skin sensor designed to continuously monitor heart health. The device is implanted during a simple, two-minute outpatient procedure and then runs passively in the background of a patient’s daily life.
What makes this device different, however, is the data it collects — and what it does with it.
Unlike traditional cardiac monitors that focus mainly on electrical signals, Future Cardia’s captures multiple data streams including heart rhythm, heart and lung sounds, and patient motion. This information is transmitted to a smartphone and analyzed using AI to detect early warning signs of heart failure.
Instead of waiting for symptoms to become severe enough for a hospital visit, doctors can be alerted earlier and potentially prevent emergencies altogether.
Heart failure affects roughly six million Americans and drives more than forty billion dollars in annual-healthcare costs. These costs are largely due to repeated hospitalizations.
To make money, Future Cardia plans to sell its implantable devices to hospitals, cardiology clinics, and healthcare providers. It’ll also generate recurring revenue through monitoring services and data analytics.
Future Cardia’s device has been implanted in nearly forty patients and generated more than 60,000 hours of cardiac data. The company has also raised around eighteen million dollars to date.